RenovoRx (RenovoRx) EBIT per Share : $-0.93 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RenovoRx EBIT per Share?

RenovoRx's EBIT per Share for the three months ended in Mar. 2024 was $-0.17. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.93.

During the past 3 years, the average EBIT per Share Growth Rate was -42.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for RenovoRx's EBIT per Share or its related term are showing as below:

RNXT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -42.6 Med: -37.9 Max: -33.2
Current: -42.6

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of RenovoRx was -33.20% per year. The lowest was -42.60% per year. And the median was -37.90% per year.

RNXT's 3-Year EBIT Growth Rate is ranked worse than
87.15% of 1300 companies
in the Biotechnology industry
Industry Median: 3.4 vs RNXT: -42.60

RenovoRx's EBIT for the three months ended in Mar. 2024 was $-2.48 Mil.

RenovoRx EBIT per Share Historical Data

The historical data trend for RenovoRx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx EBIT per Share Chart

RenovoRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.46

-0.38

-1.05

-1.10

-1.11

RenovoRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.36	-0.32	-0.28	-0.17	-0.17

RenovoRx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

RenovoRx's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.396	/	10.291
=	-1.11

RenovoRx's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.476	/	14.948
=	-0.17

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93

RenovoRx (NAS:RNXT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

RenovoRx EBIT per Share Related Terms

Thank you for viewing the detailed overview of RenovoRx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

RenovoRx (RenovoRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022

Website

https://www.renovorx.com

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.

Executives

Angela Nelms	officer: Chief Operating Officer	C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers	officer: Chief Financial Officer	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah	director, officer: Chief Medical Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai	director, officer: Chief Executive Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West	10 percent owner	PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman	officer: Chief Financial Officer	65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners	officer: Chief Financial Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303